BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 2026/7/241 分で読めます

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). This meeting was announced in the Federal Register on June 30, 2026. The amendment is being made to reflect a change in the DATES, ADDRESSES, and SUPPLEMENTARY INFORMATION: Procedure portion of the document. There are no other changes.

情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →

関連インサイト

ビジネスインサイト →